華恆生物(688639.SH):擬透過全資子公司對外投資 建設巴彥淖爾項目
格隆匯6月10日丨華恆生物(688639.SH)公佈,公司為完善產業鏈,進一步擴展業務範圍,提高收益水平,擬以全資子公司巴彥淖爾華恆生物科技有限公司(“巴彥淖爾華恆”)為實施主體,投資不超過2.5億元人民幣,建設“巴彥淖爾華恆生物科技有限公司年產1.6萬噸三支鏈氨基酸及其衍生物項目”(以下簡稱“項目”)。該項目預計建設期為18個月,項目建設地點位於巴彥淖爾市杭錦後旗陝壩鎮工業園區。
公吿顯示,該次投資項目有利於公司完善三支鏈氨基酸產品品種,擴大公司業務範圍,豐富產品種類,增加市場競爭力,為把巴彥淖爾華恆建成公司生物大發酵基地打好基礎,符合公司的戰略發展需要,有助於公司的長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.